MX2015012731A - Procesos e intermedios para preparar un medicamento. - Google Patents

Procesos e intermedios para preparar un medicamento.

Info

Publication number
MX2015012731A
MX2015012731A MX2015012731A MX2015012731A MX2015012731A MX 2015012731 A MX2015012731 A MX 2015012731A MX 2015012731 A MX2015012731 A MX 2015012731A MX 2015012731 A MX2015012731 A MX 2015012731A MX 2015012731 A MX2015012731 A MX 2015012731A
Authority
MX
Mexico
Prior art keywords
intermediates
processes
medicament
preparing
useful
Prior art date
Application number
MX2015012731A
Other languages
English (en)
Inventor
Matteo Conza
Philip Pye
Haim Cyril Ben
Ioannis Nicolaos Houpi
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2015012731A publication Critical patent/MX2015012731A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulga un proceso para preparar los siguientes compuestos:(ver Fórmula) en donde R1, R1a y R2a son como se han definido en la memoria descriptiva, así como también un proceso para preparar otros intermedios que pueden ser útiles para sintetizar productos posteriores, especialmente compuestos que son útiles como medicamentos, por ejemplo, inhibidores de la tirosina-cinasa de Bruton (Btk) tal como ibrutinib; también se divulgan otros procesos, otros intermedios y compuestos perse.
MX2015012731A 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento. MX2015012731A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361786842P 2013-03-15 2013-03-15
EP13159470 2013-03-15
EP13197813 2013-12-17
PCT/EP2014/054621 WO2014139970A1 (en) 2013-03-15 2014-03-11 Processes and intermediates for preparing a medicament

Publications (1)

Publication Number Publication Date
MX2015012731A true MX2015012731A (es) 2016-02-18

Family

ID=51535892

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012731A MX2015012731A (es) 2013-03-15 2014-03-11 Procesos e intermedios para preparar un medicamento.
MX2020012596A MX2020012596A (es) 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020012596A MX2020012596A (es) 2013-03-15 2015-09-14 Procesos e intermedios para preparar un medicamento.

Country Status (19)

Country Link
EP (1) EP2970291B1 (es)
JP (1) JP6777398B2 (es)
KR (2) KR102311329B1 (es)
CN (2) CN112608298A (es)
AU (2) AU2014230935A1 (es)
BR (1) BR112015021856A2 (es)
CA (1) CA2901510C (es)
DK (1) DK2970291T3 (es)
EA (1) EA201591685A1 (es)
ES (1) ES2924193T3 (es)
HR (1) HRP20220628T1 (es)
HU (1) HUE058914T2 (es)
LT (1) LT2970291T (es)
MX (2) MX2015012731A (es)
MY (1) MY194905A (es)
PE (1) PE20151652A1 (es)
SG (2) SG10201809696UA (es)
SI (1) SI2970291T1 (es)
WO (1) WO2014139970A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2846652C (en) 2011-09-02 2019-11-05 Incyte Corporation Heterocyclylamines as pi3k inhibitors
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105884747B (zh) * 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN104447761A (zh) * 2014-11-27 2015-03-25 广东东阳光药业有限公司 一种吡唑衍生物的制备方法
CN105481862B (zh) * 2015-01-21 2018-08-21 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
EP3248979B1 (en) * 2015-01-21 2021-04-14 Hefei Institutes of Physical Science, Chinese Academy of Sciences Novel inhibitor of flt3 kinase and use thereof
ES2843522T3 (es) 2015-02-27 2021-07-19 Incyte Corp Sales del inhibidor de PI3K y procesos para su preparación
LV15201B (lv) 2015-08-31 2017-07-20 Latvijas Organiskās Sintēzes Institūts Ibrutiniba izejvielas iegūšanas paņēmiens
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018145280A1 (zh) * 2017-02-09 2018-08-16 合肥合源药业有限公司 Flt3激酶抑制剂或其盐的晶型及其制备方法
CN107383017B (zh) * 2017-07-20 2020-01-14 河南师范大学 依鲁替尼高效制备方法
JP7166331B2 (ja) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間体化合物及び方法
KR20220011668A (ko) 2019-05-21 2022-01-28 얀센 파마슈티카 엔.브이. Btk 억제제 제조를 위한 방법 및 중간체
BR112021022646A2 (pt) * 2019-05-21 2022-03-29 Janssen Pharmaceutica Nv Processos e intermediários para a preparação de um inibidor de btk
CN113200987A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼的制备方法
CN115322226B (zh) * 2022-08-17 2023-08-11 厦门大学 一种共价靶向砷抑制剂及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1212327T3 (da) * 1999-09-17 2003-12-15 Abbott Gmbh & Co Kg Pyrazolopyrimidiner som terapeutiske midler
EP2532235A1 (en) * 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2403546T3 (es) * 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
CA2681756C (en) * 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
ES2460019T3 (es) 2009-03-31 2014-05-13 Boehringer Ingelheim International Gmbh Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de PDE9A
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8962830B2 (en) 2010-07-09 2015-02-24 The Walter And Eliza Hall Institute Of Medical Research Protein kinase inhibitors and methods of treatment
US9273028B2 (en) * 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
EP2731612A4 (en) * 2011-07-13 2015-04-08 Pharmacyclics Inc BRUTON TYROSINE KINASE HEMMER
MX2015001802A (es) * 2012-08-10 2015-05-07 Boehringer Ingelheim Int Compuestos heteroaromaticos como inhibidores de btk.
KR101668574B1 (ko) * 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
CN103848810A (zh) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
HUE058914T2 (hu) 2022-09-28
EA201591685A1 (ru) 2016-01-29
MY194905A (en) 2022-12-22
KR102311329B1 (ko) 2021-10-14
KR102377688B1 (ko) 2022-03-22
DK2970291T3 (da) 2022-08-01
AU2018204086B2 (en) 2020-03-12
BR112015021856A2 (pt) 2017-07-18
KR20210123429A (ko) 2021-10-13
LT2970291T (lt) 2022-06-10
CN112608298A (zh) 2021-04-06
AU2018204086A1 (en) 2018-06-28
CN105026400A (zh) 2015-11-04
EP2970291B1 (en) 2022-05-11
AU2014230935A1 (en) 2015-09-03
HRP20220628T1 (hr) 2022-06-24
WO2014139970A1 (en) 2014-09-18
KR20150132172A (ko) 2015-11-25
JP2016510779A (ja) 2016-04-11
EP2970291A1 (en) 2016-01-20
ES2924193T3 (es) 2022-10-05
SI2970291T1 (sl) 2022-07-29
JP6777398B2 (ja) 2020-10-28
SG10201809696UA (en) 2018-11-29
SG11201507595XA (en) 2015-10-29
MX2020012596A (es) 2021-02-09
PE20151652A1 (es) 2015-11-12
CA2901510C (en) 2022-11-29
CA2901510A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015012731A (es) Procesos e intermedios para preparar un medicamento.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
SA515360007B1 (ar) مركبات عطرية غير متجانسة كمثبطات بروتونز تيروسين كيناز ( btk)
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
MX2016003582A (es) Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
MY173877A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
MX336214B (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
MD20150048A2 (ro) Derivaţi ai pirolotriazinonei în calitate de inhibitori ai PI3K
MX348470B (es) Pirimidinas anilladas sustituidas y uso de las mismas.
EA201492005A1 (ru) Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX2016000794A (es) Composiciones farmaceuticas de pancreatina de potencia alta.
MY175804A (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
PH12015502000A1 (en) Processes and intermediates for preparing a medicament
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof

Legal Events

Date Code Title Description
HH Correction or change in general